Printer friendly version
HiberGene Diagnostics Ltd Appoints new Chief Executive Officer
01 November 2012
NovaUCD - The Innovation and Technology Transfer Centre at University College Dublin
HiberGene Diagnostics, an Irish diagnostics company utilising the latest medical technology to develop, market and manufacture molecular diagnostic tests for human infectious diseases, has announced the appointment of Tony Hill as Chief Executive Officer.
HiberGene is based at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin, Ireland.
Tony joins HiberGene from Innogenetics, an international diagnostics company, where he was Global Sales Director. Prior to this, Tony was Vice-President at OraSure Technologies, and earlier roles included a number of positions at Sigma Aldrich.
Tony has a wealth of experience from more than 20 years in the diagnostic and life science industries. He brings with him, expertise in general management and marketing and sales, coupled with a strong track record in growing domestic and international markets.
Brendan Farrell, Executive Chairman of HiberGene, said, “I am delighted to have secured someone of Tony’s calibre to lead HiberGene. He has a great range of experience across diagnostics and life sciences, coupled with a strong track record of success.”
Tony Hill, Chief Executive Officer of HiberGene added, “This is a very exciting time to be joining HiberGene. The company has developed an excellent test for meningitis using a very innovative platform, which fills a significant unmet clinical need.”
HiberGene have developed a molecular diagnostic test for Meningococcus and plan also to develop a test for Pneumococcal Meningitis, the two most common forms of meningitis.
Using a novel rapid amplification platform, HiberGene have produced a rapid and highly sensitive diagnostic test which can be used in almost any clinical or laboratory setting.
The company is currently fundraising to progress the tests for meningitis through to commercialisation and to fund further ongoing research and development on a complementary range of human infectious diseases.